NPR News·5 min read·medium
Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
B
Bobby Allyn
✦AI Summary
Prediction markets like Kalshi and Polymarket are facing criticism for allowing users to bet on the success or failure of clinical trials. Critics argue that these bets commodify patient suffering and death, turning medical outcomes into financial instruments.
As a soon-to-be seventh grader, Joshua Pederson's son is not exactly brimming with enthusiasm when he talks about the upcoming school year.
businesshealthtechnology
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in